Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[Q]: CES is allowing space for sex tech companies as a one-year trial. At the show, such companies were scattered throughout the health and wellness section, near startups pitching fitness trackers and infrared saunas. Lora DiCarlo, a startup that pushed for changes after organizers revoked its award, showed off its Ose robotic "personal massager." It's one of a dozen companies at the show focused on vibrators, lube dispensers and other sex tech products. Founders of these startups say their products are about empowerment and wellness for women, something they say has often been overlooked in tech. The historically male-dominated tech trade show has received criticism in past years for having an all-male lineup of speakers and for previously allowing scantily clad "booth babes," fostering a "boys' club" reputation. Besides allowing sex tech, CES organizers brought in an official "equality partner," The Female Quotient, to help ensure gender diversity. The Female Quotient, which trains companies in equality practices, will hold a conference for women during the four-day show, which opened Tuesday. "It's been a process," said Gary Shapiro, the head of the Consumer Technology Association, which puts on CES. It's been a longer process for many sex tech companies to convince investors that they are part of a growing trend that has enough customers. Much of the push has come from the startups' female founders and from younger consumers who talk more openly about sexuality. As with other technologies, some exhibitors including Lora DiCarlo had prominent booths at CES, while others such as the wearable vibrator company Crave were tucked away. Crave's exhibit included a camper with a "Build-a-Vibe-Workshop," where attendees could get an engraved vibrator to wear around their neck. Sex tech has existed in some form for decades. But the gates really began to open in 2016, said Andrea Barrica, founder of sex education site O.school. That year, several other "fem tech" companies made progress in areas such as menstruation and menopause. Those paved the way for sex tech to grow and get investors interested. "Larger institutions are starting to take note, all the way from VC firms to large Fortune 100 companies," said Barrica, who recently published the book "Sextech Revolution: The Future of Sexual Wellness." Large institutions like CES had no choice but to look at sex tech, she said. The journey hasn't been easy. Sex tech founders, many of them women, recount being turned down by dozens of investors. They faced decency arguments and entrenched corporate standards that equated them with porn. But investors are becoming more receptive, said Cindy Gallop, a former advertising executive turned sex tech entrepreneur and founder of the website MakeLoveNotPorn. "It's entirely because of our refusal to allow the business world to put us down," she said. Founders insist that their devices ranging from vibrators to lube dispensers to accessories have effects outside the bedroom. "Sexual health and wellness is health and wellness," said Lora DiCarlo, CEO and founder of the company of the same name. "It does way more than just pleasure. It's immediately connected to stress relief, to better sleep, to empowerment and confidence." DiCarlo's $290 Ose device has gotten $3 million worth of advance sales, bolstered in part by the attention it received after CES organizers overturned a decision by an independent panel of judges to give the vibrator a prestigious Innovation Honoree Award in the robotics and drone category. The organizers, CTA, told the company it reserved the right to rescind awards for devices deemed "immoral, obscene, indecent, profane or not in keeping with CTA's image." DiCarlo and other female founders pushed back for banning them but allowing humanoid sex robots meant to serve men the previous year. Following criticism, CES organizers ultimately reinstated the award and apologized. A few months later, the show announced policy changes such as a dress code to prevent skimpy outfits and new "Innovation for All" sessions with senior diversity officials. Ose began shipping to customers this month. DiCarlo said the company is planning to introduce new devices, including less expensive options. Sex tech companies still face major barriers to growth. Polly Rodriguez, CEO of sexual wellness company Unbound, said the company is profitable and customers are more open about buying products than they once were. But she said she still faces roadblocks advertising on social media, and many traditional investors snub the company. "Things are better, but there's just still this genuine fear of female sexuality more broadly within the institutional side of technology," she said. And while Gallop offered to speak at CES, conference organizers declined, saying sex tech was not a part of its conference programming. ___ AP Business Writer Joseph Pisani contributed to this report. ___ AP's CES coverage: https://apnews.com/Consumerelectronics
[A]: Sex tech from women-led startups pops up at CES gadget show.

[Q]: Republicans on the GOP-majority Senate Environment and Public Works Committee mostly had praise for Andrew Wheeler, who has served as the agency's acting head since Scott Pruitt's resignation in July amid ethics scandals. The committee chairman, Sen. John Barrasso, R-Wyo., called Wheeler "very well-qualified" to take the job. But Democrats pressed Wheeler about his work as a lobbyist helping an influential coal magnate meet with Trump administration officials before his nomination to the EPA and his moves on deregulation and on what they said was his inattention to the growing dangers of climate change. "You seem to be consistently doing things that undermine the health and safety of this nation," Sen. Ed Markey, D-Mass., told Wheeler. Markey asked him why he was pulling back on regulations that proponents say protect human health and the environment. "I believe we are moving forward" on protections, Wheeler responded. Wheeler cited changes he had initiated to roll back future mileage standards for cars and autos and to ease Obama-era clampdowns on dirtier-burning coal-fired power plants. He said EPA staff, whom he did not identify, had concluded that those rollbacks would ultimately lead to health gains. Environmental groups and formal assessments from the EPA and other agencies have contested that, saying the changes would increase pollution and increase harm to people and the climate. Sen. Tom Carper, D-Del., said the rollbacks in car mileage standards and toxic mercury emissions under Wheeler were examples of unsafe deregulation and went beyond what industries themselves wanted. Sen. Bernie Sanders, I-Vt., noted Wheeler had failed to mention climate change in his initial remarks to lawmakers. "Do you agree that climate change is a global crisis?" Sanders asked, shouting at times. "I would not call it the greatest crisis," Wheeler said. "I would call it a huge issue that has to be addressed globally." Wheeler told lawmakers that he had yet to read a massive government climate change report released late last year that emphasized man-made climate change was already underway. Wheeler said he had received one staff briefing so far on the climate change report. The work of the EPA and other government agencies, the report stresses the massive economic toll expected from increasingly severe wildfires, hurricanes and other extreme weather under climate change. Wheeler said the news media had seized upon "worst-case scenarios" of the climate report. "You are a former coal industry lobbyist that is sitting here," Markey responded. "That's the worst-case scenario, what you are proposing here" for easing Obama-era rules meant to clamp down on climate-changing fossil fuel emissions. Sen. Joni Ernst of Iowa and other Republican lawmakers, by contrast, praised Wheeler for a move to remove federal protections for millions of miles of wetlands and waterways and other proposals. Republican lawmakers said the protections had burdened farmers and others. The grandson of a coal miner, Wheeler worked for the EPA in the 1990s and later as a longtime Republican Senate staffer. Democrats pressed Wheeler about his lobbying before joining the EPA, saying his work for coal companies should disqualify him from leading an agency that regulates coal. Wheeler's lobbying clients included coal magnate Bob Murray, who pushed hard on the Trump administration after the 2016 elections to grant a series of breaks for the sagging domestic coal industry. Wheeler accompanied Murray to a March 2017 meeting to pitch Murray's list of desired rule rollbacks and other breaks for coal to Energy Secretary Rick Perry. Wheeler told senators that his main work for Murray had been on health benefits and pensions. "I did not work on the plan. I do not have a copy of it. I saw it briefly," Wheeler said, referring to Murray's wish list. Sen. Sheldon Whitehouse, D-R.I., displayed a blown-up version of a photo taken of the meeting with Perry, showing Wheeler at Murray's side. A second photo showed Murray's rollback plan in Wheeler's hands. Murray had sought some of the coal breaks that the EPA under Wheeler has since acted on. That included Wheeler signing a rule easing federal regulation of toxic coal ash, redoing an Obama rule that pushed electricity providers to move away from dirtier-burning coal plants and targeting an Obama rule limiting emissions of toxic mercury from coal plants. A watchdog group, Citizens for Responsibility and Ethics in Washington, filed an ethics complaint Tuesday with the EPA's Office of the Inspector General alleging that Wheeler's oversight of those and other rollback proposals at EPA may have violated his government ethics pledge to abstain from regulatory decisions affecting his former lobbying client for at least two years. EPA spokesman John Konkus called the accusation "baseless" and "wrong" and said Wheeler works with EPA ethics officials and follows their guidance.
[A]: Democrats hit Trump EPA nominee on coal lobbying, rollbacks.

[Q]: The company declined to discuss details in the so-called not approvable letter from the Food and Drug Administration. It would not comment on whether the agency had asked for further data or new clinical trials. The drug, which was expected to be called Cordaptive, combines long-acting niacin with a new drug that prevents the flushing side effect common to niacin an uncomfortable sensation of burning in the face and neck that leads many patients to discontinue taking it. Analysts widely expected the drug to be approved, especially after a committee of European regulators last week recommended it be cleared for sale there. The rejection was another blow for Merck, whose share price has fallen about 30 percent this year amid a controversy and debate over the effectiveness of the cholesterol drugs its sells in a joint venture with Schering-Plough Corp. The FDA decision should be a boon to Abbott Laboratories, whose franchise of niacin-based cholesterol drugs would have been in direct competition with Merck's proposed new entry into the lucrative market. Abbott shares rose 2.7 percent following the Merck news. Deutsche Bank analyst Barbara Ryan called the news a disappointment. "We expected the drug to get approved," she said. "It's not going to have any impact on the earnings outlook for this year, but certainly as we go out in time they could have had an important contribution from the drug." Merck said it would meet with the FDA to submit additional information to enable the agency to further evaluate the benefit/risk profile of the drug, which it has gone back to calling MK-0524A after the FDA also rejected the prospective brand name Cordaptive. "We firmly believe that MK-0524A provides physicians with an important option to manage their patients' cholesterol," Merck's research chief Peter Kim said in a statement. The company said it did not yet know when a meeting with FDA officials might take place. In clinical trials, the laropiprant component of the drug demonstrated an ability to significantly reduce the flushing effect of niacin. It had been hoped the combination would enable patients to tolerate niacin at a dose that provides the most therapeutic benefit. Despite the setback, Merck reaffirmed the 2008 forecast it issued last week and reiterated confidence in meeting its goal of double-digit annual earnings per share growth through 2010, excluding certain items. Some analysts believed that Cordaptive and a planned follow-up combination drug that also includes Merck's bad cholesterol lowering Zocor could eventually garner $1 billion to $2 billion in annual sales. Merck shares fell to $39.40 in extended trading from their New York Stock Exchange close at $41.44, while Abbott shares climbed to $53 from the NYSE close at $51.61.
[A]:
Merck says FDA rejects its new cholesterol drug.